Matthieu Boiteau
About Matthieu Boiteau
Matthieu Boiteau is the Regional Director Field Medical Hematology and Oncology at Bristol-Myers Squibb in the United States, with extensive experience in oncology and hematology.
Title
Matthieu Boiteau is the Regional Director Field Medical Hematology and Oncology at Bristol-Myers Squibb. In this role, he leads initiatives in hematology and oncology within the United States, coordinating efforts to enhance field medical operations and strategic direction.
Experience at Genentech
Matthieu Boiteau worked at Genentech for a total of 7 years in various capacities. He served as the National Lead of the Nurse Field Team from 2010 to 2015 in the San Francisco Bay Area. Prior to that, he was a Group Product Manager from 2008 to 2010 and a Senior Product Manager Oncology from 2005 to 2008. During his tenure, he contributed significantly to oncology product management and team leadership.
Experience at Sanofi
At Sanofi, Matthieu Boiteau held several key positions over a span of 5 years. He was the Senior Product Manager from 2004 to 2005 and District Sales Manager from 2002 to 2004 in New Jersey. Additionally, he served as International Global Product Manager from 2000 to 2002. His time at Sanofi saw him managing various product lines and sales teams, enhancing their strategic impact.
Education and Academic Background
Matthieu Boiteau studied at Sorbonne Universités, where he achieved a Master of Business Administration (MBA) from 1994 to 1996. He also holds a Doctor of Pharmacy (Pharm.D.) degree from Université Paris Descartes, completed between 1988 and 1995. This educational background combines his pharmaceutical expertise with advanced business management skills.
Expertise in Oncology and Hematology
Matthieu Boiteau has significant expertise in oncology, covering various types of cancers such as lung, renal, melanoma, head and neck, hepatocellular carcinoma, and gastrointestinal cancers. He also has a robust background in hematology, dealing with conditions like chronic myeloid leukemia, Hodgkin lymphoma, multiple myeloma, myelodysplastic syndromes, and acute myeloid leukemia. He has managed portfolios inclusive of both solid tumors and hematologic malignancies.